SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Patounet who wrote (247)3/15/1998 8:11:00 PM
From: Steve Goldstein  Read Replies (1) | Respond to of 783
 
Patounet,
Your message certainly caught my attention. I have been waiting for Glaxo (or someone else) to buy them. Their PER is pretty stiff right now, e.g., apprx 42. Some things have to be in the pipeline that allows BCHE to carry on at these levels. It was a $30+ stock not that long ago. Hope your right.



To: Patounet who wrote (247)3/15/1998 9:56:00 PM
From: John Metcalf  Respond to of 783
 
Thanks, Patounet. Are you sure this is something new and not a rehash of Lamivudine for HBV?



To: Patounet who wrote (247)3/17/1998 9:53:00 PM
From: Wilfredo Pagani  Read Replies (2) | Respond to of 783
 
Lamouduline or 3tc which is the other retroviral agent of Glaxo combivir is the medication that was aproved by the British Drugs for chronic hepatitis b infection that as you said affect hundreds of millions chinese patients. This had not yet been aproved by FDA. It seems to be some problems with the cost to the China goverment for such a therapy. I agree if this problems are solved stock will increased and probably may be bought by Glaxo WPagani


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News